首頁 > 市場調查報告書 > 醫療設備

生物材料

市場調查報告書

商品編碼

1917886

聚合物生物材料市場－2026-2031年預測

Polymeric Biomaterials Market - Forecast from 2026 to 2031

出版日期: 2026年01月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計聚合物生物材料市場將從 2025 年的 561.86 億美元成長到 2031 年的 1,315.89 億美元，複合年成長率為 15.24%。

聚合物生物材料市場是一個基礎性強且發展迅速的領域，它位於材料科學、工程和醫學的交叉領域。這些材料被定義為合成或天然聚合物，經過工程設計可與生物系統相互作用，並在體內發揮特定功能，涵蓋結構支撐、藥物傳輸、組織再生和器械整合等。它們獨特的性能，例如可調控的分解速率、機械強度、生物相容性和表面功能性，使其能夠應用於包括整形外科、循環系統醫學、神經病學和牙科在內的眾多醫學領域。市場成長的驅動力來自材料科學的進步、人口結構和疾病趨勢帶來的臨床需求成長，以及向個人化和再生醫學解決方案的模式轉移。

推動聚合物生物材料成長要素源自於臨床對先進治療和再生醫學應用日益成長的需求。聚合物生物材料在再生醫學領域至關重要，可作為組織工程的支架、可控藥物和基因傳遞的載體以及微創細胞移植的注射基質。透過設計具有精確分解特性和生物活性訊號的聚合物，可以建構支持組織修復和再生的微環境。這種能力對於滿足複雜創傷治療、器官修復和慢性退化性疾病治療等領域的未滿足需求至關重要，使聚合物生物材料成為下一代治療方法的關鍵平台。

同時，慢性及老齡化肌肉骨骼疾病（MSDs）在全球範圍內的日益普遍是推動市場發展的關鍵因素。骨關節炎、脊髓退化以及創傷或疾病導致的骨缺損等疾病，使得整形外科植入和骨移植替代材料的需求顯著增加。包括聚乳酸-羥基乙酸共聚物（PLGA）和聚己內酯（PCL）等可生物分解聚合物在內的聚合物生物材料，被廣泛應用於縫合線、固定裝置和可吸收支架中，這些材料在提供臨時機械支撐的同時，還能促進自然癒合。向生物活性可吸收植入的轉變，避免了二次取出手術的需要，是推動整形外科領域創新和應用的關鍵趨勢。

人口結構變化，尤其是全球人口老化，進一步推動了市場的持續擴張。老年人患有需要醫療干預的疾病（例如心血管疾病、關節退化性疾病和牙科疾病）的比例更高。這一人口趨勢正在推動對各種植入器材的需求，從支架和心臟瓣膜到關節重建和牙科修補，其中許多器械的功能和生物相容性都依賴聚合物組件。長期植入對耐用、無血栓形成性和抗感染材料的需求，持續推動先進聚合物化學領域的研究和開發。

技術創新是推動市場發展和創造機會的持續動力。目前的研究重點在於開發具有增強功能的「智慧型」聚合物系統，例如刺激響應型藥物釋放、固有抗菌性能以及調節免疫反應的能力。生物可吸收聚合物和共聚物的研發是產業相關人員的關鍵策略方向。這些材料旨在為患者提供指定時間內所需的機械支撐，然後分解為可安全代謝的產物，從而消除長期異物風險和二次手術取出的需要。共聚物設計、共混和表面改質方面的創新旨在更好地控制分解速率、機械性能以及與宿主組織的整合。

從區域來看，北美憑藉主導系統、充足的公共和私人生物醫學創新資金（例如透過國家科學基金會等機構）以及成熟的醫療設備產業（擁有完善的監管和商業化體系），保持著領先地位。大型製藥和醫療技術公司的存在，促進了材料科學突破快速轉化為臨床產品。同時，亞太地區被公認為高成長市場，其成長動力來自不斷成長的醫療費用支出、不斷擴大的醫療基礎設施、日益提升的國內製造能力，以及區域和全球企業為加強其在新興經濟體的業務而採取的戰略舉措。

在競爭格局中，特種化學品製造商、生醫材料專家和大型醫療設備製造商是主要參與者。關鍵策略活動包括對新型聚合物合成和配方技術進行研發投資、與學術和臨床研究機構建立策略聯盟，以及專注於獲得新材料適應症的監管核准。各公司也正在投資擴大臨床級材料的生產規模，以滿足大規模治療應用的需求。

總之，聚合物生物材料市場對現代醫學的發展至關重要，為創新醫療設備和再生醫學提供了必要的材料基礎。其成長軌跡與個人化醫療、微創治療以及應對全球老化人口複雜慢性疾病等前沿領域密切相關。未來市場參與企業的成功將取決於其設計具有日益複雜生物相互作用的聚合物的能力，透過嚴格的臨床檢驗證明其安全性和有效性，以及應對力植入材料相關複雜監管環境的能力。聚合物科學的持續發展有望開創新的治療模式，確保該市場在塑造未來醫療保健格局中發揮核心作用。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 按來源
- 依產品類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 按來源
- 依產品類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 按來源
- 依產品類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 德國
  - 法國
  - 英國
  - 西班牙
  - 其他
中東和非洲
- 按來源
- 依產品類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 按來源
- 依產品類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 印尼
  - 泰國
  - 台灣
  - 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第11章公司簡介

Corbion
Evonik Industries
Mitsubishi Chemical Group
DSM-Firmenich
Covestro
Bezwada Biomedical, LLC
Stryker Corporation
Victrex Plc
Reva Medical, LLC
NatureWorks LLC（Cargill Incorporated）

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615901

Polymeric Biomaterials Market, with a 15.24% CAGR, is expected to grow to USD 131.589 billion in 2031 from USD 56.186 billion in 2025.

The polymeric biomaterials market constitutes a foundational and rapidly evolving segment at the intersection of materials science, engineering, and medicine. Defined as synthetic or natural polymers designed to interact with biological systems, these materials are engineered to perform specific functions within the body, ranging from structural support and drug delivery to tissue regeneration and device integration. Their unique properties-including tunable degradation rates, mechanical strength, biocompatibility, and surface functionality-enable their application across a broad spectrum of medical fields, including orthopedics, cardiovascular medicine, neurology, and dentistry. Market growth is propelled by the convergence of advancing material science, rising clinical demand driven by demographic and disease trends, and a paradigm shift towards personalized and regenerative medical solutions.

A primary and powerful growth driver is the escalating clinical demand for advanced therapeutic and regenerative applications. Polymeric biomaterials are indispensable in the field of regenerative medicine, serving as scaffolds for tissue engineering, carriers for controlled drug and gene delivery, and as injectable matrices for minimally invasive cell transplantation. The ability to engineer polymers with precise degradation profiles and bioactive cues allows for the creation of supportive microenvironments that guide tissue repair and regeneration. This capability is critical for addressing unmet needs in complex wound healing, organ repair, and the treatment of chronic degenerative diseases, positioning polymeric biomaterials as enablers of next-generation therapies.

Parallel to this, the increasing global prevalence of chronic and age-related musculoskeletal disorders (MSDs) is a significant market catalyst. Conditions such as osteoarthritis, spinal degeneration, and bone defects resulting from trauma or disease generate substantial demand for orthopedic implants and bone graft substitutes. Polymeric biomaterials, including biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL), are extensively used in sutures, fixation devices, and resorbable scaffolds that provide temporary mechanical support while promoting natural bone healing. The shift towards bioactive and resorbable implants that eliminate the need for secondary removal surgeries is a key trend, driving innovation and adoption in the orthopedic segment.

Demographic shifts, specifically the aging of the global population, further underpin sustained market expansion. Older adults exhibit a higher incidence of conditions requiring medical intervention, such as cardiovascular disease, joint degeneration, and dental pathologies. This demographic trend amplifies the demand for a wide array of implantable devices-from stents and heart valves to joint replacements and dental prosthetics-many of which rely on polymeric components for their functionality and biocompatibility. The need for durable, non-thrombogenic, and infection-resistant materials in long-term implants continues to drive research and development in advanced polymer chemistries.

Technological innovation is a constant driver of market evolution and opportunity. Ongoing research focuses on developing "smart" polymeric systems with enhanced functionalities, such as stimuli-responsive drug release, inherent antimicrobial properties, and the ability to modulate immune responses. A significant strategic focus for industry participants is the advancement of bioresorbable polymers and copolymers. These materials are engineered to provide necessary mechanical support for a defined period before safely degrading into metabolizable byproducts, thereby eliminating long-term foreign body risks and the need for secondary surgical removal. Innovations in copolymer design, blending, and surface modification are aimed at achieving superior control over degradation kinetics, mechanical properties, and integration with host tissue.

Geographically, North America maintains a leading position, supported by a robust ecosystem of academic research, substantial public and private funding for biomedical innovation (through agencies like the National Science Foundation), and a mature medical device industry with strong regulatory and commercialization pathways. The presence of major pharmaceutical and medical technology companies fosters rapid translation of material science breakthroughs into clinical products. Concurrently, the Asia-Pacific region is identified as a high-growth market, driven by increasing healthcare expenditure, expanding medical infrastructure, rising domestic manufacturing capabilities, and strategic initiatives by both regional and global companies to establish a stronger presence in these emerging economies.

The competitive landscape features specialty chemical companies, dedicated biomaterial firms, and large medical device corporations. Key strategic activities include significant investment in R&D for novel polymer synthesis and formulation, strategic partnerships with academic and clinical research centers, and a focus on securing regulatory approvals for new material indications. Companies are also investing in scaling up manufacturing processes for clinical-grade materials to meet the demands of large-scale therapeutic applications.

In conclusion, the polymeric biomaterials market is integral to the advancement of modern medicine, providing the essential material building blocks for innovative medical devices and regenerative therapies. Its growth trajectory is firmly linked to the frontiers of personalized medicine, minimally invasive interventions, and the treatment of an aging global population with complex chronic conditions. Future success for market participants will hinge on the ability to engineer polymers with increasingly sophisticated biological interactions, demonstrate safety and efficacy through rigorous clinical validation, and navigate the complex regulatory landscapes governing implantable materials. The ongoing evolution of polymer science promises to unlock new therapeutic paradigms, ensuring the market's central role in shaping the future of healthcare.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Polymeric Biomaterials Market Segmentation

By Source
Natural
Synthetic
By Product Type
Polylactic Acid (PLA)
Polyglycolic Acid (PGA)
Polyurethane (PU)
Polypropylene
Others
By Application
Neurology
Cardiology
Orthopedic
Ophthalmology
Wound Care
Others
By End-User
Hospitals
Specialty Clinics
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. POLYMERIC BIOMATERIALS MARKET BY SOURCE

5.1. Introduction
5.2. Natural
5.3. Synthetic

6. POLYMERIC BIOMATERIALS MARKET BY PRODUCT TYPE

6.1. Introduction
6.2. Polylactic Acid (PLA)
6.3. Polyglycolic Acid (PGA)
6.4. Polyurethane (PU)
6.5. Polypropylene
6.6. Others

7. POLYMERIC BIOMATERIALS MARKET BY APPLICATION

7.1. Introduction
7.2. Neurology
7.3. Cardiology
7.4. Orthopedic
7.5. Ophthalmology
7.6. Wound Care
7.7. Others

8. POLYMERIC BIOMATERIALS MARKET BY END-USER

8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics
8.4. Others

9. POLYMERIC BIOMATERIALS MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Source
- 9.2.2. By Product Type
- 9.2.3. By Application
- 9.2.4. By End-User
- 9.2.5. By Country
  - 9.2.5.1. USA
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. South America
- 9.3.1. By Source
- 9.3.2. By Product Type
- 9.3.3. By Application
- 9.3.4. By End-User
- 9.3.5. By Country
  - 9.3.5.1. Brazil
  - 9.3.5.2. Argentina
  - 9.3.5.3. Others
9.4. Europe
- 9.4.1. By Source
- 9.4.2. By Product Type
- 9.4.3. By Application
- 9.4.4. By End-User
- 9.4.5. By Country
  - 9.4.5.1. Germany
  - 9.4.5.2. France
  - 9.4.5.3. United Kingdom
  - 9.4.5.4. Spain
  - 9.4.5.5. Others
9.5. Middle East and Africa
- 9.5.1. By Source
- 9.5.2. By Product Type
- 9.5.3. By Application
- 9.5.4. By End-User
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
  - 9.5.5.2. UAE
  - 9.5.5.3. Others
9.6. Asia Pacific
- 9.6.1. By Source
- 9.6.2. By Product Type
- 9.6.3. By Application
- 9.6.4. By End-User
- 9.6.5. By Country
  - 9.6.5.1. China
  - 9.6.5.2. India
  - 9.6.5.3. Japan
  - 9.6.5.4. South Korea
  - 9.6.5.5. Indonesia
  - 9.6.5.6. Thailand
  - 9.6.5.7. Taiwan
  - 9.6.5.8. Others